|
[1]
|
Xie, Z., Xu, Y., Song, Y., Wang, Y., Han, X., Sun, A., et al. (2025) De Novo Heart Failure in Patients Hospitalized with St-Segment Elevation Myocardial Infarction in Contemporary China. Cardiology Plus, 10, 10-22. [Google Scholar] [CrossRef]
|
|
[2]
|
Angermann, C.E. and Ertl, G. (2025) China’s Fight against New-Onset Heart Failure after Acute Myocardial Infarction: A Major Stage Victory. Cardiology Plus, 10, 5-9. [Google Scholar] [CrossRef]
|
|
[3]
|
(2021) 2020 Expert Consensus on the Prevention and Treatment of Heart Failure after Myocardial Infarction: Branch of Cardio-Vascular Physicians, Chinese Medical Doctor Association, Chinese Cardiovascular Association, The Expert Consensus Working Group on the Prevention and Treatment of Heart Failure after Myocardial Infarction. Cardiology Plus, 6, 4-20. [Google Scholar] [CrossRef]
|
|
[4]
|
Jivraj, N., Phinikaridou, A., Shah, A.M. and Botnar, R.M. (2013) Molecular Imaging of Myocardial Infarction. Basic Research in Cardiology, 109, Article No. 397. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Prabhu, S.D. and Frangogiannis, N.G. (2016) The Biological Basis for Cardiac Repair after Myocardial Infarction: From Inflammation to Fibrosis. Circulation Research, 119, 91-112. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Teringova, E. and Tousek, P. (2017) Apoptosis in Ischemic Heart Disease. Journal of Translational Medicine, 15, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Bhatt, A.S., Ambrosy, A.P. and Velazquez, E.J. (2017) Adverse Remodeling and Reverse Remodeling after Myocardial Infarction. Current Cardiology Reports, 19, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Sackner-Bernstein, J.D. (2000) The Myocardial Matrix and the Development and Progression of Ventricular Remodeling. Current Cardiology Reports, 2, 112-119. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Swirski, F.K. and Nahrendorf, M. (2018) Cardioimmunology: The Immune System in Cardiac Homeostasis and Disease. Nature Reviews Immunology, 18, 733-744. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Guo, C., Ji, W., Yang, W., Deng, Q., Zheng, T., Wang, Z., et al. (2023) NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post‐Myocardial Infarction via Human Antigen R. Advanced Science, 10, Article ID: 2303283. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Contessotto, P., Spelat, R., Ferro, F., Vysockas, V., Krivickienė, A., Jin, C., et al. (2023) Reproducing Extracellular Matrix Adverse Remodelling of Non-ST Myocardial Infarction in a Large Animal Model. Nature Communications, 14, Article No. 995. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wang, Y., Zhang, Y., Li, J., Li, C., Zhao, R., Shen, C., et al. (2023) Hypoxia Induces M2 Macrophages to Express VSIG4 and Mediate Cardiac Fibrosis after Myocardial Infarction. Theranostics, 13, 2192-2209. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Matsui, Y. (2010) Role of Matricellular Proteins in Cardiac Tissue Remodeling after Myocardial Infarction. World Journal of Biological Chemistry, 1, 69-80. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Oliveira, J.B., Soares, A.A.S.M. and Sposito, A.C. (2018) Inflammatory Response during Myocardial Infarction. Advances in Clinical Chemistry, 84, 39-79. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zaidi, Y., Aguilar, E.G., Troncoso, M., Ilatovskaya, D.V. and DeLeon-Pennell, K.Y. (2021) Immune Regulation of Cardiac Fibrosis Post Myocardial Infarction. Cellular Signalling, 77, Article ID: 109837. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Westman, P.C., Lipinski, M.J., Luger, D., Waksman, R., Bonow, R.O., Wu, E., et al. (2016) Inflammation as a Driver of Adverse Left Ventricular Remodeling after Acute Myocardial Infarction. Journal of the American College of Cardiology, 67, 2050-2060. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
DeLeon-Pennell, K.Y., Meschiari, C.A., Jung, M. and Lindsey, M.L. (2017) Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science, 147, 75-100. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Ciarka, A., Borne, P.V.D. and Pathak, A. (2008) Myocardial Infarction, Heart Failure and Sympathetic Nervous System Activity: New Pharmacological Approaches That Affect Neurohumoral Activation. Expert Opinion on Investigational Drugs, 17, 1315-1330. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Mladěnka, P., Hrdina, R., Bobrovová, Z., Semecký, V., Vávrová, J., Holečková, M., et al. (2009) Cardiac Biomarkers in a Model of Acute Catecholamine Cardiotoxicity. Human & Experimental Toxicology, 28, 631-640. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Mann, D.L., Kent, R.L., Parsons, B. and Cooper, G. (1992) Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte. Circulation, 85, 790-804. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Olivetti, G., Capasso, J.M., Meggs, L.G., Sonnenblick, E.H. and Anversa, P. (1991) Cellular Basis of Chronic Ventricular Remodeling after Myocardial Infarction in Rats. Circulation Research, 68, 856-869. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, J.A., et al. (1997) Apoptosis in the Failing Human Heart. New England Journal of Medicine, 336, 1131-1141. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Osadchii, O.E., Norton, G.R., McKechnie, R., Deftereos, D. and Woodiwiss, A.J. (2007) Cardiac Dilatation and Pump Dysfunction without Intrinsic Myocardial Systolic Failure Following Chronic β-Adrenoreceptor Activation. American Journal of Physiology-Heart and Circulatory Physiology, 292, H1898-H1905. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Patel, S., Rauf, A., Khan, H. and Abu-Izneid, T. (2017) Renin-Angiotensin-Aldosterone (RAAS): The Ubiquitous System for Homeostasis and Pathologies. Biomedicine & Pharmacotherapy, 94, 317-325. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Chen, L., Ding, M., Wu, F., He, W., Li, J., Zhang, X., et al. (2016) Impaired Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Hypertensive Patients with Primary Hyperaldosteronemia. Hypertension, 67, 430-439. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Sayer, G. and Bhat, G. (2014) The Renin-Angiotensin-Aldosterone System and Heart Failure. Cardiology Clinics, 32, 21-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Abuzaanona, A. and Lanfear, D. (2017) Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Current Heart Failure Reports, 14, 536-542. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Husebye, T., Eritsland, J., Müller, C., Sandvik, L., Arnesen, H., Seljeflot, I., et al. (2013) Levosimendan in Acute Heart Failure Following Primary Percutaneous Coronary Intervention‐Treated Acute St‐elevation Myocardial Infarction. Results from the LEAF Trial: A Randomized, Placebo‐Controlled Study. European Journal of Heart Failure, 15, 565-572. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
O’Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., et al. (2011) Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 365, 32-43. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Pirracchio, R., Parenica, J., Resche Rigon, M., Chevret, S., Spinar, J., Jarkovsky, J., et al. (2013) The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis. PLOS ONE, 8, e71659. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Thiele, H., Zeymer, U., Thelemann, N., Neumann, F., Hausleiter, J., Abdel-Wahab, M., et al. (2019) Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction. Circulation, 139, 395-403. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Mogensen, U.M., Køber, L., Kristensen, S.L., Jhund, P.S., Gong, J., Lefkowitz, M.P., et al. (2017) The Effects of Sacubitril/Valsartan on Coronary Outcomes in Paradigm-HF. American Heart Journal, 188, 35-41. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Zhao, Y., Luo, J., Pang, K., Feng, Y., Tan, J., Liu, M., et al. (2025) Clinical Efficacy of Sacubitril/Valsartan Combined with Cardiac Rehabilitation in Patients with Heart Failure after Acute Myocardial Infarction: A Single-Center Randomized Trial. BMC Cardiovascular Disorders, 25, Article No. 246. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Gu, T., Zhang, Y., Hu, S., Zhang, J., Wu, X., Liu, X., et al. (2025) Differences in the Efficacy of β-Blocker Therapy after Acute Myocardial Infarction in Different Types of Heart Failure. Journal of the American College of Cardiology, 85, 1652. [Google Scholar] [CrossRef]
|
|
[35]
|
Guo, X., Yang, W., Cui, Y., Guo, R., Zhu, Y., Liu, T., et al. (2025) Long-Term Safety and Efficacy of Ivabradine after Direct Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Complicated by Heart Failure: A Single-Center Retrospective Study. BMC Cardiovascular Disorders, 25, Article No. 422. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
James, S., Erlinge, D., Storey, R.F., McGuire, D.K., de Belder, M., Eriksson, N., et al. (2024) Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence, 3, 1-11. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Butler, J., Jones, W.S., Udell, J.A., Anker, S.D., Petrie, M.C., Harrington, J., et al. (2024) Empagliflozin after Acute Myocardial Infarction. New England Journal of Medicine, 390, 1455-1466. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Butler, J., Anstrom, K.J. and Armstrong, P.W. (2020) Comparing the Benefit of Novel Therapies across Clinical Trials: Insights from the VICTORIA Trial. Circulation, 142, 717-719. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Armstrong, P.W., Pieske, B., Anstrom, K.J., Ezekowitz, J., Hernandez, A.F., Butler, J., et al. (2020) Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 382, 1883-1893. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Galván Ruiz, M., Fernández de Sanmamed Girón, M., del Val Groba Marco, M., Rojo Jorge, L., Peña Saavedra, C., Martín Bou, E., et al. (2024) Clinical Profile, Associated Events and Safety of Vericiguat in a Real‐World Cohort: The VERITA Study. ESC Heart Failure, 11, 4222-4230. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Malik, F.I., Hartman, J.J., Elias, K.A., Morgan, B.P., Rodriguez, H., Brejc, K., et al. (2011) Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. Science, 331, 1439-1443. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Teerlink, J.R., Diaz, R., Felker, G.M., McMurray, J.J.V., Metra, M., Solomon, S.D., et al. (2021) Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 384, 105-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Teerlink, J.R., Diaz, R., Felker, G.M., McMurray, J.J.V., Metra, M., Solomon, S.D., et al. (2021) Effect of Ejection Fraction on Clinical Outcomes in Patients Treated with Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 78, 97-108. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., et al. (2003) Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The Charm-Preserved Trial. The Lancet, 362, 777-781. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R., et al. (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 359, 2456-2467. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Cleland, J.G.F. (2006) The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) Study. European Heart Journal, 27, 2338-2345. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Lund, L.H., Claggett, B., Liu, J., Lam, C.S., Jhund, P.S., Rosano, G.M., et al. (2018) Heart Failure with Mid‐Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan across the Entire Ejection Fraction Spectrum. European Journal of Heart Failure, 20, 1230-1239. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Solomon, S.D., McMurray, J.J.V., Anand, I.S., Ge, J., Lam, C.S.P., Maggioni, A.P., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 381, 1609-1620. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
McMurray, J.J.V., Jackson, A.M., Lam, C.S.P., Redfield, M.M., Anand, I.S., Ge, J., et al. (2020) Effects of Sacubitril-Valsartan versus Valsartan in Women Compared with Men with Heart Failure and Preserved Ejection Fraction. Circulation, 141, 338-351. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Pitt, B., Pfeffer, M.A., Assmann, S.F., Boineau, R., Anand, I.S., Claggett, B., et al. (2014) Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370, 1383-1392. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Fukuta, H., Goto, T., Wakami, K., Kamiya, T. and Ohte, N. (2020) Effect of Beta-Blockers on Heart Failure Severity in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials. Heart Failure Reviews, 26, 165-171. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Silverman, D.N., Plante, T.B., Infeld, M., Callas, P.W., Juraschek, S.P., Dougherty, G.B., et al. (2019) Association of β-Blocker Use with Heart Failure Hospitalizations and Cardiovascular Disease Mortality among Patients with Heart Failure with a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Network Open, 2, e1916598. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Anker, S.D., Butler, J., Filippatos, G., Ferreira, J.P., Bocchi, E., Böhm, M., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385, 1451-1461. [Google Scholar] [CrossRef] [PubMed]
|